Key Points
- Director Quiros Juan Jose Chacon sold 67,249 shares on May 1 at an average price of $70.78 for proceeds of $4.76 million, leaving him with 1,040,255 shares (a 6.07% reduction in his stake).
- Those May 1 trades were part of a larger selling program—he sold a total of 225,000 shares between March 23 and May 4, generating roughly $14.94 million in proceeds.
- For context, Establishment Labs has a market cap of about $2.06 billion, a 52‑week range of $32.25–$83.31, and a consensus analyst rating of “Moderate Buy” with a $86.86 target.
Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $70.48, for a total value of $546,290.48. Following the completion of the sale, the director directly owned 1,032,504 shares in the company, valued at approximately $72,770,881.92. This represents a 0.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Quiros Juan Jose Chacon also recently made the following trade(s):
- On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The shares were sold at an average price of $70.78, for a total value of $4,759,884.22.
- On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The shares were sold at an average price of $66.26, for a total value of $144,446.80.
- On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The shares were sold at an average price of $65.78, for a total value of $1,985,108.84.
- On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total transaction of $2,790,066.06.
- On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
- On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
- On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.
Establishment Labs Trading Up 0.0%
Shares of NASDAQ:ESTA opened at $70.24 on Tuesday. The company's 50-day moving average price is $65.53 and its two-hundred day moving average price is $66.03. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs Holdings Inc. has a one year low of $32.25 and a one year high of $83.31. The stock has a market capitalization of $2.06 billion, a PE ratio of -40.37 and a beta of 1.12.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm had revenue of $64.62 million for the quarter, compared to analysts' expectations of $63.80 million. During the same period in the previous year, the firm posted ($1.19) EPS. The company's revenue for the quarter was up 45.2% on a year-over-year basis. On average, equities analysts forecast that Establishment Labs Holdings Inc. will post -0.86 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
ESTA has been the subject of several recent analyst reports. Canaccord Genuity Group increased their price objective on Establishment Labs from $85.00 to $90.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Needham & Company LLC increased their price objective on Establishment Labs from $84.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, February 24th. Citigroup cut their price objective on Establishment Labs from $81.00 to $74.00 and set a "neutral" rating for the company in a report on Wednesday, March 11th. BTIG Research reissued a "buy" rating and issued a $88.00 price objective on shares of Establishment Labs in a report on Wednesday, April 29th. Finally, Stephens lifted their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $86.86.
Check Out Our Latest Analysis on ESTA
Hedge Funds Weigh In On Establishment Labs
Large investors have recently made changes to their positions in the company. Quarry LP bought a new position in shares of Establishment Labs during the third quarter worth approximately $34,000. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs during the fourth quarter worth approximately $47,000. State of Wyoming bought a new position in shares of Establishment Labs during the third quarter worth approximately $71,000. Osaic Holdings Inc. raised its stake in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after purchasing an additional 1,800 shares in the last quarter. Finally, MV Capital Management Inc. acquired a new stake in Establishment Labs in the 4th quarter worth about $146,000. Institutional investors own 72.91% of the company's stock.
Establishment Labs Company Profile
(
Get Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
